NRx Pharmaceuticals Total Non-Operating Income/Expense 2018-2024 | NRXP

NRx Pharmaceuticals total non-operating income/expense from 2018 to 2024. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.

NRx Pharmaceuticals Total Non-Operating Income/Expense 2018-2024 | NRXP

NRx Pharmaceuticals total non-operating income/expense from 2018 to 2024. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$88.3B
Takeda Pharmaceutical (TAK)$46.6B
Merck (MKGAF)$23B
Astellas Pharma (ALPMY)$21.6B
Sandoz Group AG (SDZNY)$18.1B
Summit Therapeutics (SMMT)$16.5B
United Therapeutics (UTHR)$15.9B
Shionogi (SGIOY)$13.3B
Neurocrine Biosciences (NBIX)$11.7B
Catalent (CTLT)$10.9B
Orion OYJ (ORINY)$7.7B
Revolution Medicines (RVMD)$7.3B
Jazz Pharmaceuticals (JAZZ)$6.8B
Ionis Pharmaceuticals (IONS)$6B
Hikma Pharmaceuticals Plc (HKMPF)$5.7B
Madrigal Pharmaceuticals (MDGL)$4.6B
Corcept Therapeutics (CORT)$4.5B
Crinetics Pharmaceuticals (CRNX)$4B
Dyne Therapeutics (DYN)$3.5B
PTC Therapeutics (PTCT)$2.9B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Arrowhead Pharmaceuticals (ARWR)$2.4B
Catalyst Pharmaceuticals (CPRX)$2.4B
Recursion Pharmaceuticals (RXRX)$2B
Soleno Therapeutics (SLNO)$1.9B
Centessa Pharmaceuticals (CNTA)$1.8B
Xencor (XNCR)$1.6B
Harrow (HROW)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.6B
Cassava Sciences (SAVA)$1.5B